anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a transparent cosmetic, having high safety, stability with time, touch and cleansing effects, etc., by adding and blending a blend of an alkyl phosphate based activator with a large amount of a liquid oily substance in a blend of a polyhydric alcohol with water. CONSTITUTION:A transparent skin cosmetic obtained by adding and blending a blend of an alkyl phosphate based nonionic activator, e.g. a compound expressed by formula I, and/or alkyl phosphate based anionic activator, e.g. a compound expressed by formula II (R1-R3 are ethylene group or propylene group (R4-R6 are 8-22C alkyl or alkenyl; l, m and n are 0-30) in an amount of 0.5-10% based on the weight of the final composition with a liquid oily substance, e.g. liquid paraffin, squalane or oleic acid, in an amount of 40-90% based on the weight of the final composition in a blend of a polyhydric alcohol in an amount of 5-59% based on the weight of the final composition (in an amount of >=4 times based on the weight of water) with water in an amount of 0.5-15% based on the weight of the final composition while stirring. The cosmetic is extremely useful as a gelatinous cleansing cream, nourishing oil, etc., which can be washed away.
This invention is directed to methods for preventing the emergence of multidrug resistance in tumor cells during cancer chemotherapy. In particular, it relates to the use of protein kinase inhibitors to prevent the induction of expression of the multidrug resistance gene (MDR1) encoding P-glycoprotein by chemotherapeutic drugs. MDR1 expression, which results in tumor cell resistance to subsequent treatment with certain chemotherapeutic drugs, is shown herein to be induced in response to treatment with various cytotoxic agents, including such agents that are and are not substrates for P-glycoprotein-mediated efflux from cancer cells. Inhibitors of protein kinases, in particular protein kinase C, are shown herein to suppress this cellular response. In addition, such protein kinase inhibitors are also shown herein to inhibit expression of a gene encoding a multidrug resistance-associated protein (the MRP gene). The instant invention provides methods for using such protein kinase inhibitors to both suppress induction of MDR1 gene expression by cytotoxic drugs, and to inhibit expression of MRP. The invention also provides methods for identifying protein kinase inhibitors that have either or both of these effects on MDR1 and MRP expression. Thus, the invention provides useful methods and reagents for preventing the emergence of multidrug resistance in tumor cells treated with cytotoxic and chemotherapeutic drugs in cancer patients undergoing chemotherapy, when such protein kinase inhibitors are administered prior to or simultaneous with cytotoxic drug treatment in such individuals.
Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
Mothers of an infant are much less likely to exercise regularly compared with women who have older children or no children. This low level of physical activity (PA) contributes to postpartum weight retention which can predict levels of obesity up to 15 years later. Ethnic minorities have higher rates of inactivity and gain more weight following childbirth, which places them at increased risk for cancer and other chronic diseases consistent with known health disparities for these ethnic groups. Few PA interventions have been designed to increase PA in women with an infant, especially ethnic minority women. This study will test the efficacy of a tailored intervention to increase and maintain PA in a multiethnic population of 268 young, healthy postpartum women living in Hawaii. Women will be recruited from health care settings, mother/baby support groups, and from the media campaigns(TV, radio, newspaper, parents magazines). Subjects will be randomly assigned to either a tailored postpartum counseling intervention on PA or standard care for PA. The tailored PA intervention will address key personal, social, and environmental factors derived from Social Cognitive Theory and the Transtheoretical Model. Also, multimodal contacts (telephone, e-mail, website) will be used to deliver theoretically-derived, culturally sensitive PA counseling,behavioral skills training (e.g., goal setting), and local resources/referrals tailored to a mother with an infant. The standard care condition receives American Heart Association/American College of Sports Medicine print materials/e-mails and referral to PA internet resources.

The primary PA outcome is minutes of moderate/vigorous physical activity (MVPA) per week, as measured by the Active Australia Questionnaire, with validation by accelerometers worn by all subjects. Condition differences in the initiation of PA will be tested at 6 and 12 months post-baseline. Key psychosocial, physiological, and cultural factors will be tested as mediators or moderators of PA, for example: self-efficacy, social support, processes of change, ethnicity, BMI, and cultural values. This study will serve as a model for the design and implementation of PA interventions for at-risk ethnic minority postpartum women.
NEW MATERIAL:The peptide antibiotic substance Bu-2517 of formula (Pro is proline; Ser is serine; Arg is arginine; beta-OH-Asp is threo-beta-hydroxyaspartic acid; 3-OH-Pro is trans-3-hydroxyproline) or its salt. USE:Antibacterial agent inhibiting the growth of aerobic and anaerobic Gram- positive bacteria. PROCESS:A bacterial strain belonging to Empedobacter genus and capable of producing Bu-2517 (e.g. G393-B445 strain) is cultured in an aqueous nutrient medium containing assimilable carbon and nitrogen under submerged aerobic conditions at 7-42 deg.C, preferably at 27-32 deg.C usually for 2-7 days. The cultured product is extracted with a water-immiscible organic solvent such as n-butanol, evaporated to dryness, dissolved in an organic solvent, and diluted with an antisolvent (e.g. acetone) to precipitate crude Bu-2517, which is purified by ion exchange chromatography using an anion exchange resin.
This study aimed to analyze anthropometric and physiological profiles of highly trained sailors and the differences between sailors regarding various training levels. Forty-two sailors (22 male, 22.4 ± 3.8 years; 20 females, 21.3 ± 3.6 years) were divided into helmsmen and crew groups, and the high- and low-level were distinguished. Sailors completed height, sitting height, legs length, weight, BMI, VO2max, 30 s all-out sprint, isometric mid-thigh pull (IMTP), countermovement jump, bench pull, core endurance tests. The results showed the crew had higher height, sitting height, weight, VO2max and lower trunk flexor endurance test times compared to the helmsmen (p < 0.05). The helmsmen had higher relative peak power/force in the 30 s all-out sprint and IMTP tests compared to the crew, whereas the crew had better absolute strength in bench pull, with significant differences between female sailors (p < 0.05). The high-level sailors showed more sailing experience than low-level sailors (p < 0.05). In conclusion, highly trained crew tend to be taller and heavier, while helmsmen have better trunk flexor endurance. For female sailors, helmsmen have better lower-body power and strength and crew have better upper-body strength. Sailing experience is a reliable variable to distinguish sailors' levels. The specific anthropometric and physiological profiles of sailors in various positions can assist sailing coaches in athlete selection and intervention training.
BACKGROUND: Inflammation plays a pivotal role in the pathogenesis of heart failure (HF). This study was aimed to the potential association between complete blood cell count (CBC)-derived inflammatory biomarkers and HF.
METHODS: Data from the National Health and Nutrition Examination Survey (NHANES) 2009-2018 were utilised. We evaluated the associations between HF and five systemic inflammation markers derived from CBC: systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR). Demographic characteristics, physical examinations, and laboratory data were systematically collected for comparative analysis between HF and non-HF individuals. Fitted smoothing curves and threshold effect analysis delineated the relationship. In addition, Spearman correlation and subgroup analyses were further conducted.
RESULTS: A total of 26,021 participants were categorised into HF (n = 858) and non-HF (n = 25,163) groups. After adjusting for confounding variables, SIRI, NLR, and MLR had significant positive correlations with the risk of HF. Participants in the highest quarter groups of SIRI, NLR, and MLR showed a increased risk of developing HF compared to those in the lowest quarter group. Furthermore, subgroup and sensitivity analyses indicated that SIRI, NLR, and MLR had a stronger correlation to HF (all p < 0.05). Smoothing curve fitting highlighted a nonlinear relationship between CBC-derived inflammatory biomarkers and HF.
CONCLUSIONS: Our results illustrated a significant association between elevated levels of SIRI, NLR, and MLR and an increased risk of HF. SIRI, NLR, and MLR could potentially serve as systemic inflammation hazard markers for HF.
Participants will receive anodal tDCS on the left DLPFC for 30 mins duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
BACKGROUND: Recurrent ventricular tachycardia (VT) in patients with prior myocardial infarction is associated with adverse quality of life and clinical outcomes, despite the presence of implanted defibrillators (ICDs). Suppression of recurrent VT can be accomplished with antiarrhythmic drug therapy or catheter ablation. The Ventricular Tachycardia Antiarrhythmics or Ablation In Structural Heart Disease 2 (VANISH2) trial is designed to determine whether ablation is superior to antiarrhythmic drug therapy as first line therapy for patients with ischemic cardiomyopathy and VT.
METHODS: The VANISH2 trial enrolls patients with prior myocardial infarction and VT (with one of: ≥1 ICD shock; ≥3 episodes treated with antitachycardia pacing (ATP) and symptoms; ≥5 episodes treated with ATP regardless of symptoms; ≥3 episodes within 24 hours; or sustained VT treated with electrical cardioversion or pharmacologic conversion). Enrolled patients are classified as either sotalol-eligible, or amiodarone-eligible, and then are randomized to either catheter ablation or to that antiarrhythmic drug therapy, with randomization stratified by drug-eligibility group. Drug therapy, catheter ablation procedures and ICD programming are standardized. All patients will be followed until two years after randomization. The primary endpoint is a composite of mortality at any time, appropriate ICD shock after 14 days, VT storm after 14 days, and treated sustained VT below detection of the ICD after 14 days. The outcomes will be analyzed according to the intention-to-treat principle using survival analysis techniques RESULTS: The results of the VANISH2 trial are intended to provide data to support clinical decisions on how to suppress VT for patients with prior myocardial infarction.
CLINICALTRIALS: gov registration NCT02830360.
In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
A method for determining the stability of a polysaccharide-protein conjugate vaccine comprising: a) performing high performance size exclusion liquid chromatography (HPLC-SEC, HPSEC, SEC-HPLC, SEC) on the vaccine, wherein the SEC (gel filtration, molecular sieve) comprises a set of three chromatography columns in series to obtain an eluate; b) passing the eluate through detectors to obtain the molecular weight (MW) distribution; and c) analysing the molecular weight and/or molar mass profile based on the percentage of high molecular weight (HMW), average molecular weight (AMW), and low molecular weight (LMW). The set of three chromatography columns may be connected with a guard column. The columns may have different particle sizes. The detector may be an ultraviolet (UV) detector, refractive index detector (RI), or multiangle light scattering (MALS) detector. The polysaccharide may be a bacterial capsular polysaccharide, such as a bacterial polysaccharide from Neisseria meningitidis (N. meningitidis) for example. The protein may be a carrier protein, such as CRM197, diphtheria toxin/toxoid (DT), or tetanus toxin/toxoid (TT) for example. The vaccine may be multivalent or monovalent. The invention uses HPLC-SEC to analyse a multivalent meningitidis vaccine (MenFive), wherein high molecular weights indicate aggregation and low molecular weights indicate degradation into free saccharides or protein/peptides.
Patients should be counseled that antibacterial drugs including Keflex should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Keflex is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Keflex or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
BACKGROUND: Kidney fibrosis is a hallmark of chronic kidney disease (CKD) and compromises the viability of transplanted human bone marrow-derived mesenchymal stromal cells (BM-MSCs). Hence, BM-MSCs were genetically-engineered to express the anti-fibrotic and renoprotective hormone, human relaxin-2 (RLX) and green fluorescent protein (BM-MSCs-eRLX + GFP), which enabled BM-MSCs-eRLX + GFP delivery via a single intravenous injection.
METHODS: BM-MSCs were lentiviral-transduced with human relaxin-2 cDNA and GFP, under a eukaryotic translation elongation factor-1α promoter (BM-MSCs-eRLX + GFP) or GFP alone (BM-MSCs-eGFP). The ability of BM-MSCs-eRLX + GFP to differentiate, proliferate, migrate, produce RLX and cytokines was evaluated in vitro, whilst BM-MSC-eRLX + GFP vs BM-MSCs-eGFP homing to the injured kidney and renoprotective effects were evaluated in preclinical models of ischemia reperfusion injury (IRI) and high salt (HS)-induced hypertensive CKD in vivo. The long-term safety of BM-MSCs-RLX + GFP was also determined 9-months after treatment cessation in vivo.
RESULTS: When cultured for 3- or 7-days in vitro, 1 × 106 BM-MSCs-eRLX + GFP produced therapeutic RLX levels, and secreted an enhanced but finely-tuned cytokine profile without compromising their proliferation or differentiation capacity compared to naïve BM-MSCs. BM-MSCs-eRLX + GFP were identified in the kidney 2-weeks post-administration and retained the therapeutic effects of RLX in vivo. 1-2 × 106 BM-MSCs-eRLX + GFP attenuated the IRI- or therapeutically abrogated the HS-induced tubular epithelial damage and interstitial fibrosis, and significantly reduced the HS-induced hypertension, glomerulosclerosis and proteinuria. This was to an equivalent extent as RLX and BM-MSCs administered separately but to a broader extent than BM-MSCs-eGFP or the angiotensin-converting enzyme inhibitor, perindopril. Additionally, these renoprotective effects of BM-MSCs-eRLX + GFP were maintained in the presence of perindopril co-treatment, highlighting their suitability as adjunct therapies to ACE inhibition. Importantly, no major long-term adverse effects of BM-MSCs-eRLX + GFP were observed.
CONCLUSIONS: BM-MSCs-eRLX + GFP produced greater renoprotective and therapeutic efficacy over that of BM-MSCs-eGFP or ACE inhibition, and may represent a novel and safe treatment option for acute kidney injury and hypertensive CKD.
Despite optimal antimicrobial treatment with directly observed short-course therapy (DOTS), about 5-10 percent of drug-compliant patients with cured tuberculosis (TB or MTB) relapse, usually within a year after completion of therapy. This percentage is even greater for patients that have previously been treated for TB who often are infected with multi-drug resistant (MDR) and extensively drug resistant (XDR) organisms. The People s Republic of China has the second highest number of cases of TB in the world, with a rate of 101 cases/100,000 person-years estimated for 2004. Based on the data of the 4th national TB epidemiological survey in 2000, it is estimated that there were 1.96 million instances of pulmonary TB. With an established MDR TB prevalence of 10.7 percent, there were an estimated 209,720 cases of pulmonary, bacteriology confirmed MDR TB in China in 2000. About half of all prevalent cases of TB disease in 2000 were extrapulmonary.

This prospective longitudinal natural history study will monitor 150 subjects with suspected TB at the Henan Provincial Chest Hospital during their initial response to antituberculous chemotherapy. The subjects will be divided into 3 groups of TB-infected individuals: Cohort A) acid-fast bacilli (AFB) smear positive pulmonary disease; Cohort B) smear negative pulmonary disease; and Cohort C) extra-pulmonary disease (EPTB) in order to reflect the spectrum of TB manifestations observed at Henan Provincial Chest Hospital. We will also be enrolling 45 non-TB suspects as controls (Cohort D). The control group will serve as a comparison group for exploratory immunologic and diagnostic assays that may, in the future, serve as ways to diagnose TB and/or evaluate response to therapy.

In this exploratory study, we will be looking at the change in total volume of disease as detected by computerized tomography scans of the chest at baseline, at 2 months, and at 6 months. We will also be looking at scanned regions of extrapulmonary TB. In addition, we will monitor chemotherapeutic regimen, changes in the host immune response, overall changes in clinical parameters, initial and acquired drug-resistance of the infecting isolates, and changes in bacterial and host markers in subject samples during chemotherapy. In each case, we will look for associations of these parameters with rates of disease resolution correlated with specific structural features determined by computerized tomography scanning of the sites of TB disease (with the exception of TB meningitis and cutaneous TB, for which there are no specific lesions to follow radiographically). These studies will allow us to evaluate the use of entry criteria in future clinical trials and eventual TB diagnosis confirmation using these entry categorizations. We will also be able to examine the impact of initial regimen selection, and subsequent modifications, mycobacterial strain characteristics, extent of disease, types of lesions and host immunologic response to the overall outcome of chemotherapy, as well as potentially identify surrogate markers for improving monitoring of the response to chemotherapy.
Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).
The standard procedure for HAIC is that femoral artery puncture and catheterization are performed in every cycle of treatment, a micro-catheter is inserted and located in feeding hepatic artery. The therapeutic scheme is modified FOLFOX6 regimens including oxaliplatin, leucovorin and Fluorouracil. All chemo-drugs are given by HAI. A total of 4-6 cycles of HAIC are performed and the treated efficacy is evaluated. Patient who is not suitable for loco-regional therapies after 4-6cycles of HAIC becomes to the candidate of sequential therapies of regorafenib plus ICIs. The regorafenib 80 mg/day was uses in sequential treatment. And ICIs were used intravenously at the standard dose. Patients received sequential treatment will begin no earlier than 30 days following the last HAIC procedure.
Birth Defects are accountable for the substantial surgical burden of disease worldwide. It can bring upon death, chronic illness, disability [physical or mental or both], financial burden, social stigma, abandonment, feticide and Infanticide. Availing timely and safe surgery can minimize the potential fatalities and sufferings caused by birth defects. Yet surgery is not treated as essential for the management of birth defects, especially in lower middle-income countries. It causes potentially correctable conditions to exacerbate, which can lead to death or lifelong disabilities. Surgical care cannot only correct birth defects but also can avert potential Disability Adjusted Life Years (DALYs) and financial burden. Furthermore, surgical correction facilitates social inclusion. Such transformation can be equated to "Revising Destiny". A "whole of society" approach focused on surgical care is instrumental for addressing the health, financial, and social implications of birth defects. LEVEL OF EVIDENCE V: Expert Opinion.
Felodipine is a calcium antagonist (calcium channel blocker). Felodipine is a dihydropyridine derivative that is chemically described as ± ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate. Its molecular formula is C18H19Cl2NO4 and its structural formula is:

Felodipine, USP is a light yellow to yellow crystalline powder with a molecular weight of 384.26. It is insoluble in water and is freely soluble in acetone and in methanol; very slightly soluble in heptane. Felodipine is a racemic mixture.

Felodipine extended-release tablets, USP provide extended release of felodipine. They are available as tablets containing 2.5 mg, 5 mg or 10 mg of felodipine, USP for oral administration. Inactive ingredients are: calcium silicate, castor oil polyethoxylated 40, hydroxypropyl cellulose, hypromellose, lactose monohydrate, microcrystalline cellulose, propyl gallate, sodium stearyl fumarate, titanium dioxide, and triacetin. In addition, the 2.5 mg tablet strength contains FD&C Blue 2/indigo carmine aluminum lake and iron oxide yellow and the 5 mg and 10 mg strengths contain iron oxide red.

Felodipine extended-release tablets, USP complies with USP Dissolution Test I and Test II.
The present invention relates to DNA vaccine against SARS-Coronavirus-2 (SARS-CoV-2) infection. In particular, the present invention relates to a DNA vaccine encoding the SARS-Coronavirus-2 spike protein for use in prevention or treatment of viral infection in humans and/or animals. The DNA vaccine including the DNA construct has several features in its design that together provide a more safe and broad protection against SARS-CoV-2 strains in humans and animals, e.g. mink, ferrets, pigs and cats. The DNA construct encodes the SPIKE protein derived from the pandemic strain; Wuhan-Hu-1 (MN908947). The sequence is codon optimized for high expression in human and mammalian cells and the DNA construct is inserted in a selected DNA plasmid for eukaryotic in vivo and in vitro expression. The combination of the choice of SARS-CoV-2 SPIKE sequence, codon optimization, expression in the new generation eukaryotic expression plasmid with no antibiotic resistance marker (instead the RNA-OUT system is used for safety) and delivery to the very immunogenic skin, results in protection against SARS-CoV-2 infection and covid-19 disease.